Bio-Rad Laboratories, Inc.BIO-B stock score: 63/100
$389.98 · +0.00% · Scored Nov 19, 2026
- Technical
- 66
- Fundamental
- 62
- News
- —
The reading
Bio-Rad Laboratories (BIO-B) scores 63 out of 100, which reads neutral, higher than 82% of Healthcare stocks and 85% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 62, technicals 66.
Among the fundamentals, Earnings Growth (Annual) at 100 and Earnings Growth (Quarterly) at 99 score highest, while PEG Ratio at 3 weighs the most against it.
On the daily chart, trend-following indicators average 64 and contrarian oscillators 20 — a split worth reading before trusting the technical total.
About Bio-Rad Laboratories
Bio-Rad Laboratories (BIO-B) makes products for life science research and clinical diagnostics. Its Life Science segment sells instruments and reagents such as Droplet Digital PCR systems, real-time PCR, electrophoresis and western blotting products, flow cytometry tools and chromatography resins to academic labs and biopharma companies. Its Clinical Diagnostics segment provides quality control products, blood typing systems, diabetes monitoring tests and infectious disease and autoimmune assays to hospital and reference laboratories. Much of its revenue comes from consumables used on installed instruments. The company also holds a large stake in Sartorius, a German life science company, and has Class A and Class B shares that differ mainly in voting rights.
Bio-Rad competes with Thermo Fisher Scientific, Qiagen, Danaher, Roche and Werfen, among others. Its edge rests on a broad installed base of instruments, a strong position in diagnostic quality controls and its digital PCR technology. Investors who follow BIO-B stock tend to watch core revenue growth, operating margins and cost-cutting progress. Demand from academic researchers and biotech companies, along with China, is closely followed. Changes in the value of the Sartorius stake, which can swing reported earnings, cost-saving programs and competition in digital PCR are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward BIO-B’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
62Pulling it up
Net income growth from the prior fiscal year to the latest.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Profit margins show what percentage of revenue becomes profit.
Holding it back
PEG divides the P/E ratio by the earnings growth rate.
Earnings estimates score evaluates analyst projections for future profitability.
5-year revenue growth analyzes long-term sales trajectory and consistency.
32 weighted scorers; 7 had no data today and are left out rather than counted as zero.
Technical · daily
59Pulling it up
On-Balance Volume (OBV) tracks cumulative volume flow, adding volume on up days and subtracting on down days.
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Stochastic (14) places the close within its 14-day high-low range.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Williams %R (28-period) places the close within the last 28 periods' high-low range.
Williams %R (14-period) measures where the current price sits within the recent high-low range.
65 weighted scorers.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 69 | 1 |
| Daily | 59 | 3 |
| Weekly | 67 | 2 |
| Monthly | 69 | 2 |
| Quarterly | 69 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 20, 2026 | 63 |
| Nov 19, 2026 | 63 |
| Nov 18, 2026 | 63 |
| Nov 16, 2026 | 63 |
Key facts
- Market cap
- $10.5B
- Sector
- Healthcare
- Industry
- Medical Devices
- Beta
- 1.06
- Risk grade (1–10)
- —
- Next earnings
- —
Medical Device peers
| Company | Market cap | Score |
|---|---|---|
| PEN Penumbra | $12.6B | 62 |
| SNN Smith & Nephew | $12.5B | 62 |
| BIO Bio-Rad Laboratories | $9.9B | 62 |
| PODD Insulet | $9.5B | 61 |
| BRKR Bruker | $9.5B | 52 |
| GMED Globus Medical | $9.1B | 67 |
Questions
What is BIO-B's stock rating today?
BIO-B scores 63/100 (Neutral) as of Nov 19, 2026: technical 66, fundamental 62. Scores are recomputed every night.
What does Bio-Rad Laboratories do?
Bio-Rad Laboratories (BIO-B) makes products for life science research and clinical diagnostics. Its Life Science segment sells instruments and reagents such as Droplet Digital PCR systems, real-time PCR, electrophoresis and western blotting products, flow cytometry tools and chromatography resins to academic labs and biopharma companies.
Is BIO-B stock a buy?
The score is not a buy or sell recommendation. A 63 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the BIO-B score calculated?
97 weighted scorers feed it today: 32 fundamental, scored against Healthcare ranges, and 65 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/bio-b/"><img src="https://stocksscores.com/stocks/bio-b/badge.svg" alt="BIO-B stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/bio-b/)